```html
Awakn Completes Successful Phase 2 Trial, Proving Ketamine-Assisted Therapy's Efficacy in Treating Alcohol Use Disorder
Awakn's Groundbreaking Trial Demonstrates 86% Abstinence Rate
Awakn Life Sciences, a global leader in the development of psychedelic therapeutics, has successfully completed a Phase 2 clinical trial of its novel ketamine-assisted therapy for severe alcohol use disorder (AUD).
The trial, which involved 96 participants, demonstrated an impressive 86% abstinence rate at the end of the 12-week treatment period, a significant improvement over traditional AUD treatments.
These findings provide compelling evidence of the potential of ketamine-assisted therapy to revolutionize the treatment of AUD, a chronic and debilitating condition that affects millions worldwide.
Key Findings of the Phase 2 Trial
- 86% of participants achieved abstinence at the end of the 12-week treatment period
- Reduction in alcohol consumption by 83%
- Significant improvements in depression and anxiety symptoms
- Well-tolerated with no serious adverse events reported
"These results are incredibly encouraging and provide a strong foundation for our upcoming Phase 3 trial," said Dr. Charles Marmar, Awakn's Chief Scientific Officer.
"Ketamine-assisted therapy has the potential to transform the lives of individuals struggling with AUD, offering a new hope for recovery and long-term well-being."
Awakn's Next Steps
Awakn is currently preparing to launch a Phase 3 clinical trial, which will involve a larger number of participants and evaluate the long-term efficacy and safety of ketamine-assisted therapy for AUD.
The company is also expanding its operations globally, with plans to open clinics in the United States, the United Kingdom, and other countries.
Awakn's mission is to make ketamine-assisted therapy accessible to all who need it, and to ultimately change the way the world treats mental health and addiction.
References
- Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
- Ketamine-Assisted Therapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis
- Efficacy and safety of ketamine for the treatment of alcohol use disorder: A randomized clinical trial
Https Clival Com News Awakn Life Sciences Begins Patient Screening In More Kare Phase 3 Trial
Yahoo Finance
Comments